The global erythropoietin drugs market is expected to witness a slow growth rate during the forecast period. In 2016, EMEA dominated the market, followed by the Americas and APAC. India and China are the leading countries in the market in APAC. While Sandoz and Dr. Reddy's Laboratories dominate the erythropoietin (EPO) drugs market in India, the market in China is led by 3SBio and Beijing SL Pharmaceutical. EMEA is also witnessing positive growth, mainly due to an increase in the manufacture of EPO biosimilars by European vendors and the use of biosimilar products in this region. However, the situation in the US is complicated due to the formation of a new legislative body to govern biosimilar products. Overall, the global erythropoietin drugs market is anticipated to grow at a CAGR of 0.79% during the forecast period.

PART 01: Executive summary

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Biosimilars: Overview

Comparative analysis of biosimilars and generics

Biosimilars market opportunities

Challenges for new entrants

PART 06: Erythropoietin: An overview

Clinical uses of EPO

Abusive uses of EPO

Risks of EPO use

PART 07: Market landscape

Market overview

Five forces analysis

PART 08: Pipeline portfolio

Phase III pipeline portfolio

Phase II pipeline portfolio

Phase I pipeline portfolio

Pre-clinical pipeline portfolio

PART 09: Marketed products portfolio

PART 10: Market segmentation by end-user

Hospitals

Retail pharmacies

PART 11: Market segmentation by application

End-stage renal disease

Cancer

HIV

Wounds and neural disease

PART 12: Market segmentation by product

First-generation erythropoietin formulation

Second-generation erythropoietin formulation

Biosimilars

PART 13: Geographical segmentation

Erythropoietin drugs market in EMEA

Erythropoietin drugs market in Europe

Erythropoietin drugs market in Americas

Erythropoietin drugs market in US

Erythropoietin drugs market in APAC

Erythropoietin drugs market in China

Erythropoietin drugs market in Japan

Market overview

PART 14: Market drivers

Rise in number of patent expiries

Need for cost-effective treatment

Increase in CKD and dialysis patient pool

PART 15: Impact of drivers

PART 16: Market challenges

Physicians' reluctance to prescribe biosimilars

Multiple manufacturing complexities

Development of alternative therapies

Complicated regulatory framework

PART 17: Impact of drivers and challenges

PART 18: Market trends

Advent of biosimilars expected to improve the treatment

rates

Outsourcing of biosimilar manufacturing activities

High growth in the emerging markets

PART 19: Vendor landscape

Competitive scenario

Other prominent vendors

PART 20: Key vendor analysis

F. Hoffmann-La Roche

Amgen

Johnson & Johnson

Kyowa Hakko Kirin

PART 21: Appendix

List of abbreviations

PART 22: Explore Technavio